source
- GSK's mRNA flu vaccine shows stronger immune response than standard shots in phase 2, prompting phase 3 launchGSK reported that its experimental mRNA seasonal influenza vaccine generated higher immune responses than both standard and high-dose flu shots in a phase-2 study involving nearly 1,000 adults. Th…
- Roche partners with China's Simcere Zaiming on $1.5 billion T-cell engager for B-cell diseasesRoche announced a licensing agreement with Simcere Zaiming, a subsidiary of China's Simcere Pharmaceutical Group, to develop a trispecific T-cell engager called SIM0660. The deal includes an upfro…